Synthesis of 5-Benzylidene-3- α -carboxy Ethyl Rhodanines and Study of their Anticancer Activity Against HeLa Cell Lines and Antibacterial Activity Against MRSA

KAVERI SUNDARAM and SUBBAN RAVI*

Department of Chemistry, Karpagam University, Coimbatore-641 021, India

*Corresponding author: E-mail: ravisubban@rediffmail.com

(Received: 11 March 2013;

Accepted: 14 November 2013)

AJC-14401

Seven novel 5-benzylidene-3- α -carboxy ethyl rhodanines were synthesized and evaluated for their *in vitro* anticancer activity against HeLa cell line by MTT assay method and antibacterial activity against *Escherichia coli* and *Bacillus cereus* by MIC method. The antibacterial activity was also evaluated against multidrug-resistant *Staphylococcus aureus* (MRSA). The synthesized compounds were characterized by IR, UV, ^1H , ^{13}C and MS spectral data. Among the synthesized compounds, **3b** was found to be more potent with HeLa cancer line with an IC_{50} value of 22.96 μM and **3f** against all the bacteria in the antibacterial activity with an MIC value of 80 $\mu\text{g/mL}$.

Key Words: 3- α -Carboxy ethyl rhodanine, MTT assay, Antibacterial activity.

INTRODUCTION

Human cervical cancer is the most common and critical cancer in women caused by human papilloma virus (HPV). There are over 100 types of human papilloma virus (HPV), many of which infect the genital tract. The genital HPVs can be subdivided into two groups. Low-risk HPV types, such as HPV 6, cause benign warts. In contrast, low-risk HPV types, such as HPV 16 and HPV 18, are associated with cervical cancer¹. Almost 80 % of the cases occur in low income or developing countries. Till now there are no effective drugs for cervical cancer. Developing an efficient and less toxic anti-cancer agent is an important and challenging goal in medicinal chemistry. So we need enhance the effective anticancer drugs. Rhodanine scaffold is many biologically active compounds². In our ongoing investigations on rhodanines and have tested for the cytotoxicity properties against leukemic CEM cells. The results suggested that the rhodanine affects the cell viability by inhibiting cell division probably by interfering with DNA replication and induce apoptosis^{3,4}. In addition, the rhodanine showed strong antiproliferative activity against human leukemic CEM cells⁵. Rhodanine and related heterocycles can most probably be caused by their affinity to anti-cancer agents, such as JNK-stimulating phosphate-1 (JSP-1)⁶, tumor necrosis factor⁷, antiapoptotic biocomplex $\text{BCLX}_L \text{BH}_3$ ⁸ etc. Also these compounds have been reported for their hepatitis C virus NS5B polymerase⁹, capthesin D¹⁰, antibacterial^{11,12}, antidiabetic¹³, antifungal¹⁴, antiviral¹⁵, antiinflammatory¹⁶ and analgesic activities¹⁷. So far they were not tested for their anti-

cancer activity against cervical cancer cell lines (HeLa). So in the present work we have synthesized seven 5-benzylidene-3- α -carboxy ethylrhodanine derivatives and screened for their *in vitro* anticancer activity. Further they were also screened for anti MRSA and antibacterial activity.

EXPERIMENTAL

The synthesis of the seven new 5-benzylidene-3- α -carboxy ethyl rhodanines (**3a-g**) was illustrated in **Scheme-I**. The substituted aromatic aldehydes (**2a-g**) was condensed with 3- α -carboxy ethyl rhodanine¹⁸ (**1**) via knoevenagel condensation¹⁹ afforded the 2-(5-benzylidene-2-thiaxo-4-thiazolidin-3yl) propanoic acids (**3a-g**) (Table-1). In the IR spectrum, the desired compounds showed broad band in the region 3400-3000 cm^{-1} due to the presence of hydroxyl group and strong band at 1730 cm^{-1} for C=O. In the ^1H NMR spectral data of the compound **3a** methyl proton appeared in the up field region at δ 1.55 (d, 3H, H-1', $J = 7.2$ Hz) and a quateret signal at δ 5.60 (q, 1H, $J = 7.2$ Hz) for H-2'. The aromatic protons appeared in the region at δ 6.00-8.00 as multiplets. In addition ^{13}C NMR spectra the peak at δ 13.00 and δ 52.00 are due to methyl (C-1') and methine (C-2') carbon atoms. The carbonyl group (C-3') appeared at δ 169.46 and the ring carbonyl (C-4) at δ 165.99. The signal at δ 192.08 was assigned to the thio carbonyl group (C-2). A cluster of peaks appeared between δ 100-160 are due to aromatic carbons.

Melting points were determined in a XT-5 digital melting point instrument and are uncorrected. IR spectra were recorded (in KBr) on a Shimadzu 360 FT-IR spectrometer. ^1H and ^{13}C

Scheme-I: Synthesis of compounds **3a-g** (a) anhydrous CH₃COONa, glacial acetic acid, 4-6 h reflux

TABLE-1
CHARACTERIZATION OF THE COMPOUNDS **3a-g**

Compounds	R	m.p. (°C)	Yield (%)
3a	3-Br	248	79
3b	4-Br	245	94
3c	2-Cl	234	76
3d	3-Cl	236	72
3e	4-CH ₃	229	83
3f	4-N(CH ₃) ₂	232	86
3g	H	214	89

NMR spectra were measured at 400 MHz on a Bruker-400 spectrometer using TMS as internal standard and DMSO-*d*₆ as solvent. MS spectra were obtained on a Shimadzu MS instrument. Elemental analyses for C, H, N and S were ± 0.04 % of the theoretical values and determined using a Perkin-Elmer 240C Elemental Analyzer.

General procedure for the preparation of compounds

3a-g: To a solution of compound **1** (0.001 mol) and the respective aldehydes (**2a-f**) in glacial acetic acid were added anhydrous sodium acetate (0.001 mol). The reaction mixture was stirred under reflux for 4-6 h and then poured into ice-cold water. The precipitate was filtered, washed with water and dried. Spectral data of each compound are given below.

2-[5-(3-Bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]propanoic acid (3a): UV $\lambda_{\max}$ (nm): 374.00; IR (KBr, $\nu_{\max}$, cm⁻¹): 3400-2500 (br. band, OH), 1695 (C=O), 1602 (C=C); ¹H NMR (DMSO-*d*₆): δ 1.55 (d, *J* = 7.2 Hz, 3H, H-1'), 5.61 (q, *J* = 7.2 Hz, 1H, H-2'), 7.49 (1H, H-5''), 7.59 (1H, H-4''), 7.70 (1H, H-6''), 7.79 (s, 1H, H-6), 7.85 (1H, H-2''). ¹³C NMR (DMSO-*d*₆): δ 13.33 (C-1'), 52.87 (C-2'), 122.56 (C-5), 123.18 (C-3''), 128.61 (C-6''), 131.38 (C-2''), 131.53 (C-5''), 131.79 (C-4''), 133.51 (C-1''), 135.15 (C-6), 165.99 (C-3''), 169.46 (C-4), 192.08 (C-2). MS: *m/z* 370 (M + 1). Anal. calcd. for C₁₃H₁₀NO₃S₂Br: C, 41.94; H, 2.71; N, 3.76; S, 17.23; Found (%): C, 41.90; H, 2.73; N, 3.73; S, 17.26.

2-[5-(4-Bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]propanoic acid (3b): UV $\lambda_{\max}$ (nm): 380.00; IR (KBr, $\nu_{\max}$, cm⁻¹): 3400-2500 (br. band, OH), 1707 (C=O), 1587 (C=C); ¹H NMR (DMSO-*d*₆): δ 1.55 (d, *J* = 7.2 Hz, 3H, H-1'), 5.61 (q, *J* = 7.2 Hz, 1H, H-2'), 7.57 (d, *J* = 8.8 Hz, 2H, H-3''), 5''), 7.75 (dd, *J* = 8.8 Hz, 2H, H-2'', 6''), 7.79 (s, 1H, H-6), ¹³C NMR (DMSO-*d*₆): δ 13.34 (C-1'), 52.82 (C-2'), 122.20 (C-5), 124.81 (C-4''), 131.94 (C-3''), 132.28 (C-5''), 132.35 (C-1''), 132.48 (C-6), 166.12 (C-3'), 169.47 (C-4), 192.59 (C-2). MS:

m/z 370 (M + 1). Anal. calcd. (%) for C₁₃H₁₀NO₃S₂Br: C, 41.94; H, 2.71; N, 3.76; S, 17.23; Found (%): C, 41.96; H, 2.74; N, 3.78; S, 17.24.

2-[5-(2-Chlorobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]propanoic acid (3c): UV $\lambda_{\max}$ (nm): 364.50; IR (KBr, $\nu_{\max}$, cm⁻¹): 3400-2500 (br. band, OH), 1712 (C=O), 1595 (C=C); ¹H NMR (DMSO-*d*₆): δ 1.69 (d, *J* = 7.2 Hz, 3H, H-1'), 5.82 (q, *J* = 7.2 Hz, 1H, H-2'), 7.38 (2H, H-4'', 5''), 7.48 (2H, H-3'', 6''), 8.10 (s, 1H, H-6). ¹³C NMR (DMSO-*d*₆): δ 13.55 (C-1'), 52.76 (C-2'), 124.90 (C-5), 127.43 (C-5''), 129.26 (C-4''), 129.75 (C-6''), 130.65 (C-3''), 131.64 (C-2''), 131.71 (C-1''), 136.40 (C-6), 166.32 (C-3'), 173.65 (C-4), 192.25 (C-2). MS: *m/z* 326 (M + 1). Anal. calcd. (%) for C₁₃H₁₀NO₃S₂Cl: C, 47.63; H, 3.07; N, 4.27; S, 19.56; Found (%): C, 47.62; H, 3.11; N, 4.25; S, 19.57.

2-[5-(3-Chlorobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]propanoic acid (3d): UV $\lambda_{\max}$ (nm): 373.00; IR (KBr, $\nu_{\max}$, cm⁻¹): 3400-2500 (br. band, OH), 1695 (C=O), 1604 (C=C); ¹H NMR (DMSO-*d*₆): δ 1.54 (d, *J* = 7.2 Hz, 3H, H-1'), 5.62 (q, *J* = 7.2 Hz, 1H, H-2'), 7.55 (2H, H-2'', 4''), 7.60 (1H, H-6''), 7.67 (1H, H-5''), 7.91 (s, 1H, H-6). ¹³C NMR (DMSO-*d*₆): δ 13.52 (C-1'), 52.91 (C-2'), 125.04 (C-5), 128.22 (C-6''), 128.36 (C-2''), 129.51 (C-4''), 130.49 (C-5''), 130.69 (C-3''), 132.52 (C-1''), 134.78 (C-6), 165.92 (C-3'), 169.43 (C-4), 192.84 (C-2). MS: *m/z* 326 (M + 1). Anal. calcd. (%) for C₁₃H₁₀NO₃S₂Cl: C, 47.63; H, 3.07; N, 4.27; S, 19.56; Found (%): C, 47.67; H, 3.10; N, 4.29; S, 19.55.

2-[5-(4-Methylbenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]propanoic acid (3e): UV $\lambda_{\max}$ (nm): 364.00; IR (KBr, $\nu_{\max}$, cm⁻¹): 3400-2500 (br. band, OH), 1695 (C=O), 1585 (C=C); ¹H NMR (DMSO-*d*₆): δ 1.55 (d, *J* = 7.2 Hz, 3H, H-1'), 2.36 (3H, s, H-7''), 5.60 (q, *J* = 7.2 Hz, 1H, H-2'), 7.38 (d, *J* = 8.0 Hz, 2H, H-3'', 5''), 7.54 (d, *J* = 8.0 Hz, 2H, H-2'', 6''), 7.78 (s, 1H, H-6). ¹³C NMR (DMSO-*d*₆): δ 13.36 (C-1'), 21.13 (C-7''), 52.76 (C-2'), 120.11 (C-5), 130.07 (C-2'', 6''), 130.19 (C-3'', 5''), 130.78 (C-1''), 133.82 (C-4''), 141.79 (C-6), 166.23 (C-3'), 169.54 (C-4), 192.89 (C-2). MS: *m/z* 307 (M + 1). Anal. calcd. (%) for C₁₄H₁₃NO₃S₂: C, 54.70; H, 4.26; N, 4.56; S, 20.86; Found (%): C, 54.73; H, 4.29; N, 4.58; S, 20.82.

2-[5-(4-(Dimethylamino)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl]propanoic acid (3f): UV $\lambda_{\max}$ (nm): 459.50; IR (KBr, $\nu_{\max}$, cm⁻¹): 3400-2500 (br. band, OH), 1699 (C=O), 1570 (C=C); ¹H NMR (DMSO-*d*₆): δ 1.53 (d, *J* = 7.2 Hz, 3H, H-1'), 3.04 (6H, s, H-7'', 8''), 5.60 (q, *J* = 7.2 Hz, 1H, H-1'), 6.84 (d, *J* = 8.8 Hz, 2H, H-3'', 5''), 7.45 (d, *J* = 9.2 Hz, 2H, H-2'', 6''), 7.66 (s, 1H, H-6). ¹³C NMR (DMSO-*d*₆): δ 13.43 (C-1'), 52.60 (C-2'), 112.24 (C-7'', 8''), 112.72 (C-5), 135.16 (C-6), 152.09 (C-4''), 166.24 (C-3'), 169.72 (C-4), 192.13 (C-2). MS: *m/z* 336 (M + 1). Anal. calcd. (%) for C₁₅H₁₆N₂O₃S₂: C, 53.55; H, 4.79; N, 8.33; S, 19.06; Found (%): C, 53.58; H, 4.80; N, 8.30; S, 19.10.

2-(5-Benzylidene-4-oxo-2-thioxothiazolidine-3-yl)-propanoic acid (3g): UV $\lambda_{\max}$ (nm): 375.50; IR (KBr, $\nu_{\max}$, cm⁻¹): 3400-2500 (br. Band, COOH), 1724 (C=O) and 1589 (C=C); ¹H NMR (DMSO-*d*₆): δ 1.56 (d, *J* = 7.2 Hz, 3H, H-1'), 5.62 (q, *J* = 7.2 Hz, 1H, H-2'), 3.30 (s, 1H, H-3'), 7.55 (m, 3H, H-3'', 4'', 5''), 7.65 (dd, *J* = 7.0 Hz, 2.0 Hz, 2H, H-1'', 6''), 7.84 (s, 1H, H-6); ¹³C NMR (DMSO-*d*₆): δ 13.38 (C-1'), 52.81 (C-2'), 121.46 (C-5), 129.52 (C-2'', 6''), 130.67 (C-3'', 5''), 131.14

(C-4''), 132.84 (C-1''), 133.65 (C-6), 166.18 (C-3'), 169.48 (C-4) and 192.98 (C-2). MS: m/z 293 ($M + 1$). Anal. calcd. (%) for $C_{13}H_{11}NO_3S_2$: C, 53.22; H, 3.78; N, 4.77; S, 21.86; Found (%): C, 53.23; H, 3.75; N, 4.81; S, 21.88.

RESULTS AND DISCUSSION

Previously, we reported the synthesis and anticancer evaluation of rhodanine derivatives that possessed 3-ethylrhodanine and benzylidene or alkylidene moieties, among which 3-ethyl-5-benzylidene rhodanine (**1**) (Fig. 1) showed the strongest activity against human leukemic cells³. In the present work, as part of our ongoing research, we report the structure-based design using **1** as the lead compound, in which the modification of **1** was focused on reserving the rhodanine moiety, changing the benzylidene moiety by introducing different substituent's into the phenyl ring. This design is aimed to get more optimized structure binding to receptor easily, consequently results in their more potent activity. Moreover the N-ethyl rhodanine is replaced with α -methyl carboxy methyl rhodanine is used in the present studies against HeLa cell lines instead of human leukemic cells. Thus, a series of benzylidene rhodanine were synthesized and 7 derivatives were characterized and screened for their anticancer activity.

Fig. 1. 3-Ethyl-5-benzylidene rhodanine

The synthesized compounds **3a-g** (Table-1) was screened for the *in vitro* anticancer activity against human cervical cancer cell line HeLa by MTT assay method²⁰. All the compounds exhibited the activity. The control compound **3g** showed a moderate activity when compared to the substituted compound **3a-g**. Two electron withdrawing groups chloro (2-Cl and 3-Cl) and bromo (3-Br and 4-Br) compounds and two electron donating substituent's methyl and dimethyl amino groups in the p-position were taken up for the SAR study. The results suggested that the electron withdrawing groups have more potency than the electron donating groups. The compound **3b** exhibited highest potential against HeLa cell line with an IC_{50} 22.96 μ M (Fig. 2). Despite the compound **3a** showed less activity than compound **3b**, even though both the compounds contain the same electronegative bromo. It shows that more the electro negativity more the activity. This reason may be the position involved to determine the activity. The chloro substituent's **3c** and **3d** exhibited cytotoxicity above 100 μ M. In the series the two electron donating compounds **3e** and **3f** showed less activity with an IC_{50} above 100 μ M. The compound **3b** exhibited activity comparable to the control.

In addition to this all the synthesized compounds **3a-g** were evaluated for the *in vitro* antibacterial activity with *Escherichia coli* (gram negative), *Bacillus cereus* (gram negative) and multidrug-resistant *Staphylococcus aureus* by serial dilution method²¹ to obtain minimum inhibition concentration (MIC). The results suggested (Table-2) that the compound **3f**

Fig. 2. Cytotoxicity of compound **3b** on HeLa cell line with an IC_{50} value of 22.96 μ M

showed resistant in 80 μ g/mL concentration against *S. aureus*, *E. coli* and *B. cereus*. The electron withdrawing group derivatives **3a**, **3b**, **3c** and **3d** showed poor activity against all the strains with the MIC > 160 μ g/mL. The methyl substituent **3e** also showed moderate activity with all the strains. The compound **3f** showed good activity against all the strains. The potency of **3f** is marginally less when compared with the control drug Amikacin with an MIC value of 10 μ g/mL against all the strains. To last the antibacterial activity the compounds were screened against *S. aureus*, *E. coli* and *B. cereus*.

TABLE-2
ANTIBACTERIAL ACTIVITY OF COMPOUND **3a-g** BY MIC METHOD AGAINST MULTIDRUG-RESISTANT OF *Staphylococcus aureus* (GRAM POSITIVE), *Escherichia coli* (GRAM NEGATIVE) AND *Bacillus cereus* (GRAM POSITIVE)

Compounds	Minimum inhibition concentration (MIC) μ g/mL		
	MRSA	<i>E. coli</i> gram negative	<i>B. cereus</i> gram positive
3a	Nil	160	320
3b	320	Nil	160
3c	160	320>	320
3d	160	160	80
3e	160	320>	320
3f	80	80	80
3g	320	320	320
Amikacin	10	10	10

The more potent compound **3f** shows less cytotoxic activity which suggests that the compound does not harm the cells.

Since all the compounds exhibited the antibacterial activity they were screened against MRSA. Further it could be concluded that a free carbonyl group seem to be necessary for the anti-bacterial activity against gram-positive strains. The hypothesis that the hydrophobic amino acid substituent's at the N3-position would increase the likelihood of penetration through the bacterial cell wall and therefore potentially improve their antibacterial activity of the compounds.

Conclusion

In summary, a series of 5-benzylidene- α -carboxy ethyl rhodanine derivatives were synthesized and evaluated *in vitro* anticancer activity against human cervical cancer cell lines HeLa and *in vitro* antibacterial activity against multidrug-resistant *S. aureus*, *E. coli* and *B. cereus* pathogens. The compound **3b** showed better cytotoxicity against HeLa cell lines. In antibacterial activity compound **3f** showed good activity with all the strains.

ACKNOWLEDGEMENTS

The authors thank to Karpagam University for providing Karpagam University Research Fellowship and DST for financial assistance.

REFERENCES

- G. Dell and K. Gaston, *Cell Mol. Life Sci.*, **58**, 1923 (2001).
- T. Tomasic and L.P. Masic, *Curr. Med. Chem.*, **16**, 1596 (2009).
- B.T. Moorthy, S. Ravi, M. Srivastava, K.K. Chiruvella, H. Hamalal, O. Joy and S.C. Raghvan, *Bioorg. Med. Chem. Lett.*, **20**, 6297 (2010).
- S. Ravi, K.K. Chiruvella, K. Rajesh, V. Prabhu and S.C. Raghvan, *Eur. J. Med. Chem.*, **45**, 2748 (2010).
- S. Chandrappa, C.V. Kavitha, M.S. Shabuddin, K. Vinaya, C.S. Ananda Kumar, S.R. Ranganatha, S.C. Raghvan and K.S. Rangappa, *Bioorg. Med. Chem. Lett.*, **17**, 2576 (2009).
- N.S. Cutshall, C. O'Day and M. Prezhdo, *Bioorg. Med. Chem. Lett.*, **15**, 3374 (2005).
- P.H. Carter, P.A. Sccherle, J.A. Muckelbauer, M.E. Voss, R.Q. Liu, L.A. Thompson, A.J. Tebben, K.A. Soloman, Y.C. Lo, Z. Li, P. Strzemienski, G. Yang, N. Falahatpisheh, M. Xu, Z. Wu, N.A. Farrow, K. Ramanarayan, J. Wang, D. Rideout, V. Yalamoori, P. Domaille, D.J. Underwood, J.M. Trzskos, S.M. Friedman, R.C. Newton and C.P. Deicco, *Proc. Nat. Acad. Sci. USA*, **98**, 11879 (2001).
- A. Degterev, A. Lugovskoy, M. Cardone, B. Mulley, G. Wagner, T. Mitchison and J. Yuan, *Nat. Cell Biol.*, **3**, 173 (2001).
- T.T. Talele, P. Arora, S.S. Kulkarni, M.R. Patel, S. Singh, M. Chudayeu and N. Kaushik-Basu, *Bioorg. Med. Chem.*, **18**, 4630 (2010).
- C.A. Whitesitt, R.L. Simon, J.K. Reel, S.K. Sigmund, M.L. Phillips, J.K. Shadle, L.J. Heinz, G.A. Koppel, D.C. Hunden, S.L. Lifer, D. Berry, J. Ray, S.P. Little, X. Liu, W.S. Marshall and J.A. Panetta, *Bioorg. Med. Chem. Lett.*, **6**, 2157 (1996).
- M.X. Song, C.J. Zheng, X.Q. Deng, Q. Wang, S.P. Hou, T.T. Liu, X.L. Xing and H.R. Pio, *Eur. J. Med. Chem.*, **54**, 403 (2012).
- D. Hardej, C.R. Ashby Jr., N.S. Khadtare, S.S. Kulkarni, S. Singh and T.T. Talele, *Eur. J. Med. Chem.*, **45**, 5827 (2010).
- R. Murugan, S. Anbazhagan and S.S. Narayanan, *Eur. J. Med. Chem.*, **44**, 3272 (2009).
- K. Liaras, A. Geronikaki, J. Glamoclija, A. Ciric and M. Sokovi, *Bioorg. Med. Chem.*, **19**, 3135 (2011).
- J.H. Wu, X.H. Wang, Y.H. Yi and K.H. Lee, *Bioorg. Med. Chem. Lett.*, **13**, 1813 (2003).
- S.J. Won, C.T. Liu, L.T. Tsao, J.R. Weng, H.H. Ko, J.P. Wang and C.N. Lin, *Eur. J. Med. Chem.*, **40**, 103 (2005).
- G.S. Viana, M.A. Bandeira and F.J. Matos, *Phytomedicine*, **10**, 189 (2003).
- S. Wang, Y. Zhao, W. Zhu, Y. Liu, K. Guo and P. Gong, *Arch. Pharm. Chem. Life Sci.*, **345**, 73 (2012).
- C.L. Lee and M.M. Sim, *Tetrahedron Lett.*, **41**, 5729 (2000).
- T. Mosmann, *J. Immunol. Methods*, **65**, 55 (1983).
- Z.H. Chen, C.J. Zheng, L.P. Sun and H.R. Pio, *Eur. J. Med. Chem.*, **45**, 5739 (2010).